

Cultural Linguistic Competency (CLC) and Implicit Bias (IB)

The California legislature has passed [Assembly Bill \(AB\) 1195](#), which states that as of July 1, 2006, all Category 1 CME activities that relate to patient care must include a cultural diversity/linguistics component. It has also passed [AB 241](#), which states that as of January 1, 2022, all continuing education courses for a physician and surgeon **must** contain curriculum that includes specified instruction in the understanding of implicit bias in medical treatment.

The cultural and linguistic competency (CLC) and implicit bias (IB) definitions reiterate how patients' diverse backgrounds may impact their access to care.

The following bibliography of articles is provided to serve as a resource and adjunct to this activity.

1. [Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials.](#)
Foster M, Fergusson DA, Hawrysh T, Presseau J, Kekre N, Schwartz S, Castillo G, Asad S, Fox G, Atkins H, Thavorn K, Montroy J, Holt RA, Monfaredi Z, Lalu MM.
Res Involv Engagem. 2020 Oct 14;6:61. doi: 10.1186/s40900-020-00230-5. eCollection PMID: 33072399
2. [The landscape of CAR T-cell therapy in the United States and China: A comparative analysis.](#)
Gou L, Gao J, Yang H, Gao C.
Int J Cancer. 2019 Apr 15;144(8):2043-2050. doi: 10.1002/ijc.31924. Epub 2018 Dec 20. PMID: 30307029
3. [Bloodless chimeric antigen receptor \(CAR\) T-cell therapy in Jehovah's Witnesses.](#)
Riedell PA, Wu M, Collins JM, Gideon JM, Jakubowiak AJ, Kline JP, Kosuri S, Liu H, Smith SM, Bishop MR.
Leuk Lymphoma. 2021 Jun;62(6):1497-1501. doi: 10.1080/10428194.2021.1876868. Epub 2021 Feb 3. PMID: 33535838 No abstract available.
4. [Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care.](#)
Snyder S, Albertson T, Garcia J, Gitlin M, Jun MP.
Adv Ther. 2021 Aug;38(8):4541-4555. doi: 10.1007/s12325-021-01839-y. Epub 2021 Jul 18. PMID: 34279805
5. [CAR T in adult ALL: When and for whom?](#)
Connor MP, Frey NV.
Best Pract Res Clin Haematol. 2021 Mar;34(1):101256. doi: 10.1016/j.beha.2021.101256. Epub 2021 Feb 13. PMID: 33762110 Review.
6. [Successful Treatment of TCF3-HLF-positive Childhood B-ALL with Chimeric Antigen Receptor T-Cell Therapy.](#)
Wang T, Wan X, Yang F, Shi W, Liu R, Ding L, Tang Y, Luo C, Yang X, Ma Y, Wang X, Liang H, Li B, Lu J, Chen J.
Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):386-392. doi: 10.1016/j.clml.2021.01.014. Epub 2021 Jan 28. PMID: 33640284